giovedì, 23 marzo 2023

Notizie AIOM – anno XVII n. 729

IMWG Consensus Recommendations on Imaging in Monoclonal Plasma Disorders

June 28, 2019 - Just as newer drugs have significantly improved outcomes for patients with multiple myeloma in the past decade, newer imaging techniques are upgrading detection of the disease, leading to earlier treatment, but standards to help guide clinicians on the optimal ...
Leggi tutto

PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors

Treatment options are limited for patients with recurrent/metastatic low-grade ovarian cancers (LGOCs) and serous borderline ovarian tumors (SBOTs) as response rates to chemotherapy are low. A subset of patients appears to derive clinical benefit from antiestrogens, but ...
Leggi tutto

A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component

We conducted a multicenter, phase 2 trial using gemcitabine plus axitinib (GX) in patients with recurrent or metastatic sarcomatoid renal cell carcinoma (SRCC) to evaluate its efficacy and safety. Methods Patients with advanced RCC and a sarcomatoid component of ≥25% ...
Leggi tutto

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Pembrolizumab monotherapy has demonstrated durable antitumor activity in advanced programmed death ligand 1 (PD-L1) –expressing non‒small-cell lung cancer (NSCLC). We report 5-year outcomes from the phase Ib KEYNOTE-001 study. These data provide the longest efficacy ...
Leggi tutto

FDA Approves Bevacizumab Biosimilar

June 28, 2019 - The FDA has approved PF-06439535 (bevacizumab-bvzr), a bevacizumab biosimilar for the treatment of patients with metastatic carcinoma of the colon or rectum; unresectable advanced, metastatic, or recurrent non–small cell lung cancer (NSCLC); advanced ...
Leggi tutto

Atezolizumab Combo Approaches EU Approval for Frontline TNBC

June 28, 2019 - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the frontline combination of atezolizumab plus nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or ...
Leggi tutto

EU Panel Backs Expanded Indication of Ibrutinib Combos in CLL and Waldenstrom Macroglobulinemia

June 28, 2019 - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the indications of ibrutinib to include use in combination with obinutuzumab for adult patients with previously untreated chronic lymphocytic ...
Leggi tutto

ASCO Commends the National Academies of Sciences, Engineering, and Medicine for its Report on Guiding Cancer Control

June 28, 2019 - “We applaud the National Academies of Sciences, Engineering, and Medicine for its recommendations on cancer control in the United States. The report examines the oncology community’s efforts over the past 10 years and lays out a comprehensive ...
Leggi tutto

ASCO Launches Task Force to Address the Cancer Care Gap in Rural America

June 25, 2019 - Despite progress being made in cancer survivorship - there are currently nearly 17 million cancer survivors in the United States - not everyone is benefiting equally, especially those patients living in rural communities across America. According to “The ...
Leggi tutto

FDA Lifts Partial Clinical Hold on Venetoclax Myeloma Trial

June 24, 2019 - The FDA has lifted a partial clinical hold that was placed on the phase III CANOVA (M13-494; NCT03539744) trial, which is examining venetoclax in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma that harbors ...
Leggi tutto